CN110291102A - 促进t细胞应答的方法 - Google Patents

促进t细胞应答的方法 Download PDF

Info

Publication number
CN110291102A
CN110291102A CN201780065072.6A CN201780065072A CN110291102A CN 110291102 A CN110291102 A CN 110291102A CN 201780065072 A CN201780065072 A CN 201780065072A CN 110291102 A CN110291102 A CN 110291102A
Authority
CN
China
Prior art keywords
clec
cancer
cells
cell
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780065072.6A
Other languages
English (en)
Chinese (zh)
Inventor
E·希福洛
G·特帕泽
N·普瓦里耶
B·瓦努夫
V·高铁尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute Of Health And Medical Sciences
Universite de Nantes
OSE Immunotherapeutics SA
Original Assignee
National Institute Of Health And Medical Sciences
Universite de Nantes
OSE Immunotherapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute Of Health And Medical Sciences, Universite de Nantes, OSE Immunotherapeutics SA filed Critical National Institute Of Health And Medical Sciences
Publication of CN110291102A publication Critical patent/CN110291102A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780065072.6A 2016-10-21 2017-10-20 促进t细胞应答的方法 Pending CN110291102A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16306381 2016-10-21
EP16306381.1 2016-10-21
EP17305988.2 2017-07-24
EP17305988 2017-07-24
PCT/EP2017/076911 WO2018073440A1 (en) 2016-10-21 2017-10-20 Methods for promoting t cells response

Publications (1)

Publication Number Publication Date
CN110291102A true CN110291102A (zh) 2019-09-27

Family

ID=60293924

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780065072.6A Pending CN110291102A (zh) 2016-10-21 2017-10-20 促进t细胞应答的方法

Country Status (21)

Country Link
US (3) US11365257B2 (enExample)
EP (2) EP3950709B1 (enExample)
JP (2) JP7032396B6 (enExample)
KR (1) KR102646708B1 (enExample)
CN (1) CN110291102A (enExample)
AU (1) AU2017345286B2 (enExample)
CA (1) CA3039348C (enExample)
CY (1) CY1124584T1 (enExample)
DK (1) DK3529262T3 (enExample)
ES (2) ES2978486T3 (enExample)
HR (1) HRP20211544T1 (enExample)
HU (1) HUE056016T2 (enExample)
IL (1) IL266111B (enExample)
LT (1) LT3529262T (enExample)
MA (1) MA46570B1 (enExample)
MD (1) MD3529262T2 (enExample)
PL (1) PL3529262T3 (enExample)
RS (1) RS62463B1 (enExample)
SI (1) SI3529262T1 (enExample)
SM (1) SMT202100555T1 (enExample)
WO (1) WO2018073440A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114527285A (zh) * 2021-03-05 2022-05-24 青岛大学附属医院 C型凝集素样受体-1作为真菌性角膜炎的治疗标志物的应用
CN115151309A (zh) * 2019-12-05 2022-10-04 Ose免疫疗法 抗clec-1a抗体及其抗原结合片段

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2978486T3 (es) * 2016-10-21 2024-09-13 Ose Immunotherapeutics Métodos para promover la respuesta de linfocitos T
BR112019017751A2 (pt) 2017-02-28 2020-04-07 Vor Biopharma, Inc. composições e métodos de inibição de proteínas de linhagem específica
SG11202101994XA (en) 2018-08-28 2021-03-30 Vor Biopharma Inc Genetically engineered hematopoietic stem cells and uses thereof
CN118139884A (zh) * 2021-06-08 2024-06-04 Ose免疫疗法 人源化抗clec-1a抗体和其抗原结合片段及其模拟物
JP2024542409A (ja) * 2021-11-09 2024-11-15 オーエスイー・イミュノセラピューティクス Ｃｌｅｃ－１リガンドの同定及びその使用
CN119855827A (zh) 2022-08-01 2025-04-18 Ose免疫疗法公司 异源二聚Fc-CLEC-1融合分子及其用途
WO2025032213A1 (en) 2023-08-10 2025-02-13 Ose Immunotherapeutics Identification of hla-dra as a ligand of clec-1 and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1454215A (zh) * 1999-11-15 2003-11-05 米勒腾尼生物技术有限公司 树突状细胞特异的抗原结合片段、组合物及其使用方法、被其识别的抗原及由其获得的细胞
CN101668777A (zh) * 2007-02-23 2010-03-10 贝勒研究院 通过clec-6激活人抗原呈递细胞
US20130058957A1 (en) * 2010-02-23 2013-03-07 The University Of Tokyo Dendritic cell immunoreceptor agonist
US20160051651A1 (en) * 2014-07-21 2016-02-25 The Trustees Of The University Of Pennsylvania Treatment of cancer using a cll-1 chimeric antigen receptor

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
US5728868A (en) 1993-07-15 1998-03-17 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
EP1194152A4 (en) 1999-06-30 2002-11-06 Merck & Co Inc Links to SRC kinase inhibition
ATE309241T1 (de) 1999-09-10 2005-11-15 Merck & Co Inc Tyrosin kinase inhibitoren
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
HUP0203323A3 (en) 1999-10-19 2004-01-28 Merck & Co Inc Tyrosine kinase inhibitors and pharmaceutical compositions containing them
WO2001028993A2 (en) 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2450562A1 (en) 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003011836A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
US8246959B1 (en) 2003-08-01 2012-08-21 University Of Washington Dendritic cell-associated lectin-like molecules, compositions and methods of use
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
ES2978486T3 (es) 2016-10-21 2024-09-13 Ose Immunotherapeutics Métodos para promover la respuesta de linfocitos T

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1454215A (zh) * 1999-11-15 2003-11-05 米勒腾尼生物技术有限公司 树突状细胞特异的抗原结合片段、组合物及其使用方法、被其识别的抗原及由其获得的细胞
CN101668777A (zh) * 2007-02-23 2010-03-10 贝勒研究院 通过clec-6激活人抗原呈递细胞
US20130058957A1 (en) * 2010-02-23 2013-03-07 The University Of Tokyo Dendritic cell immunoreceptor agonist
US20160051651A1 (en) * 2014-07-21 2016-02-25 The Trustees Of The University Of Pennsylvania Treatment of cancer using a cll-1 chimeric antigen receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARCO COLONNA等: "Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells", 《EUR. J. IMMUNOL.》 *
PAMELA THEBAULT等: "The C-Type Lectin-Like Receptor CLEC-1, Expressed by Myeloid Cells and Endothelial Cells, Is Up-Regulated by Immunoregulatory Mediators and Moderates T Cell Activation", 《THE JOURNAL OF IMMUNOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115151309A (zh) * 2019-12-05 2022-10-04 Ose免疫疗法 抗clec-1a抗体及其抗原结合片段
CN114527285A (zh) * 2021-03-05 2022-05-24 青岛大学附属医院 C型凝集素样受体-1作为真菌性角膜炎的治疗标志物的应用

Also Published As

Publication number Publication date
US12091464B2 (en) 2024-09-17
EP3950709A1 (en) 2022-02-09
JP2020503252A (ja) 2020-01-30
US20190309075A1 (en) 2019-10-10
AU2017345286A1 (en) 2019-04-18
JP7404418B6 (ja) 2024-01-26
JP7032396B6 (ja) 2022-03-22
IL266111B (en) 2022-09-01
MD3529262T2 (ro) 2022-01-31
JP2022065159A (ja) 2022-04-26
KR102646708B1 (ko) 2024-03-12
ES2883678T3 (es) 2021-12-09
CA3039348A1 (en) 2018-04-26
MA46570B1 (fr) 2021-10-29
DK3529262T3 (da) 2021-09-20
HRP20211544T1 (hr) 2022-01-07
ES2978486T3 (es) 2024-09-13
IL266111A (en) 2019-06-30
HUE056016T2 (hu) 2022-01-28
JP7404418B2 (ja) 2023-12-25
PL3529262T3 (pl) 2021-12-27
SI3529262T1 (sl) 2021-12-31
LT3529262T (lt) 2021-11-10
MA46570A (fr) 2021-03-31
US11365257B2 (en) 2022-06-21
CY1124584T1 (el) 2022-07-22
US20220281983A1 (en) 2022-09-08
WO2018073440A1 (en) 2018-04-26
EP3950709B1 (en) 2024-02-14
CA3039348C (en) 2023-09-05
EP3529262A1 (en) 2019-08-28
US20240400695A1 (en) 2024-12-05
EP3529262B1 (en) 2021-07-21
RS62463B1 (sr) 2021-11-30
SMT202100555T1 (it) 2021-11-12
JP7032396B2 (ja) 2022-03-08
AU2017345286B2 (en) 2023-08-03
KR20190068605A (ko) 2019-06-18

Similar Documents

Publication Publication Date Title
JP7404418B6 (ja) Ｔ細胞応答を促進するための方法
JP6931240B2 (ja) インターロイキン−１３受容体α２ペプチド脳がんワクチン
JP6858128B2 (ja) 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
CN112469479B (zh) 治疗癌症和自身免疫性疾病的试剂和方法
EP3589654A1 (en) Antibodies having specificity to nectin-4 and uses thereof
US20230040928A1 (en) Antibodies having specificity to her4 and uses thereof
JP2022553643A (ja) 細胞傷害性ｔ細胞耐性腫瘍を治療するための組成物および方法
JP2021523098A (ja) Ｔ細胞による認識を強化するよう抗原性を調節する方法
KR20230044315A (ko) 췌장 암 평가 및 치료를 위한 방법 및 조성물
HK40007035A (en) Methods for promoting t cells response
HK40007035B (en) Methods for promoting t cells response
US20230023174A1 (en) Cd80 extracellular domain fc fusion protein regimens
TW202529780A (zh) 包含抗ｓｔｅａｐ２嵌合抗原受體ｔ細胞之治療組合
Garcia et al. SIRPo/CD172a Regulates Eosinophil Homeostasis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination